<DOC>
	<DOCNO>NCT01284517</DOCNO>
	<brief_summary>Lurasidone HCI compound candidate treatment bipolar I depression . This clinical study design test hypothesis Lurasidone combination either Lithium Divalproex effective among patient bipolar I depression .</brief_summary>
	<brief_title>Lurasidone HCI - A 6-week Phase 3 Study Patients With Bipolar I Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>1 . Provide write informed consent 18 75 year age inclusive . 2 . Meets DSMIVTR criterion bipolar I disorder , recent episode depress ( â‰¥ 4 week less 12 month ) without psychotic feature . 3 . Has lifetime history least one bipolar manic mixed manic episode . 4 . Currently treat lithium divalproex willing begin treatment lithium divalproex . 5 . Not pregnant nursing planning pregnancy within project duration study . 6 . Females reproductive potential agree remain abstinent use adequate reliable contraception throughout study least 30 day 7 . Good physical health basis medical history , physical examination , laboratory screening . 1 . Subject consider investigator imminent risk suicide injury self , others , property . 2 . Any chronic organic disease CNS ( Bipolar I Disorder ) . 3 . Hospitalization manic mixed episode within past two month . 4 . Used investigational compound within past 6 month . 5 . Clinically significant history alcohol substance abuse within past 3 month alcohol substance dependence within past 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Bipolar I Depression</keyword>
	<keyword>Lurasidone</keyword>
	<keyword>Latuda</keyword>
</DOC>